Hyundai CEO Warns Chinese Automakers Could Disrupt US Market 
Ex-Google DeepMind Researcher Warns AI Could Pose Existential Threat 
SoftBank Shares Plunge 11% After OpenAI Rules Out 2026 IPO 
Allegro Raises 2026 Outlook as International GMV Surges 
Cathie Wood Backs AI Slowdown as Safety Concerns Grow 
Japan, U.S. Discuss $19 Billion GlobalFoundries Chip Plant 
LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal 
BHP Port Hedland Wage Dispute Heads to Arbitration 
Supertanker Orders Surge as US-Iran War Reshapes Oil Trade 
Volvo Cars Plans 13 New Models by 2030 to Boost Sales 
Rosenblatt Starts Nokia at Buy on AI Networking Growth 
US Federal Register Drops Alibaba Qwen AI Search Tool 
US Court Approves airBaltic Chapter 11 Restructuring 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Databricks to Invest $350 Million in Singapore AI Expansion 
American Airlines Eyes Capacity Cuts as High Fuel Prices Persist 
Add as a preferred source on Google
SAN DIEGO, Nov. 08, 2017 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in New York, NY.
The Company will be presenting at 9:30 AM Eastern on Wednesday, November 15, 2017. A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
